Category

News
Issue 27 of Multiple Myeloma Research Review Highlights include:  Low dose lenalidomide + dexamethasone in newly diagnosed POEMS syndrome. Loss of heterozygosity indicates homologous repair deficiency in MM. Treatment intensification with SCT + lenalidomide in new MM in CR. Download here
Continue Reading
CRISPR (pronounced “crisper”) and CAR T-cell therapy are genetic technologies that have generated continued excitement during the last several years.  CRISPR is a genome editing tool that allows alteration of a genome.  Compared to other genome editing tools, it is faster, cheaper, and more accurate.  Its applications are numerous, ranging from agriculture to gene therapy....
Continue Reading
Previous studies have suggested that the progression of SMM to symptomatic multiple myeloma (MM) may be mediated by the immune system; reinforcing the immune system with a the PVX-410 vaccine may prevent or slow progression to MM. Co-administration with lenalidomide may further enhance an immune response. For this phase 1/2a study, researchers administered 6 doses...
Continue Reading
FDA approval is being sought for a once-weekly dosing option of carfilzomib (Kyprolis) for use in combination with dexamethasone as a treatment for patients with relapsed/refractory multiple myeloma. Amgen, the manufacturer of the proteasome inhibitor, announced the submission of a supplemental new drug application (sNDA) seeking this approval today. The application is based on results from the phase...
Continue Reading
Over the past 5 years, several therapies have been developed that have proven to be effective for patients with multiple myeloma. The FDA has approved several 3-drug regimens, including the combination of immunomodulatory drugs (IMiDs), a proteasome inhibitor, and dexamethasone, which is now the standard of care in the first-line setting. At this time, there...
Continue Reading
Please take 10 minutes to complete this survey to help us put myeloma on New Zealand’s health agenda and help you to have the best lives possible. The survey will be open until 3 September. https://www.surveymonkey.com/r/8YBXM78
Continue Reading
A year after the first CAR T-cell therapy was approved to treat pediatric patients with relapsed and/or refractory CD19-positive acute lymphoblastic leukemia (ALL), researchers have issued guidelines to help healthcare professionals recognize and treat the associated adverse events (AEs) from this treatment. While the guidelines are intended for all healthcare professionals—from emergency room and neurology...
Continue Reading
A supplemental biologics license application (sBLA) for elotuzumab (Empliciti) has been granted a priority review by the FDA for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (EPd) as a treatment for patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor (PI). The application is based on...
Continue Reading
Researchers are working on an “on and off” switch to improve the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy and counter the treatment’s potential negative effects, according to a Notre Dame press release. CAR T-cell therapy, which has been hailed as the “fifth pillar” of cancer treatment, is a novel treatment method that...
Continue Reading
Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses eligibly criteria for patients with multiple myeloma to receive chimeric antigen receptor (CAR) T-cell therapy. There have been very promising data published recently on the use of CAR T-cell therapy for patients with myeloma, says Madduri. The anti-BCMA CAR T-cell therapy bb2121 was granted a breakthrough...
Continue Reading
1 27 28 29 30 31 37

Floor 7, 90 The Terrace
Wellington Central
New Zealand